Introduction
The quest for an HIV vaccine continues as scientists struggle to understand how to generate effective, long-lasting immunity against HIV. Despite decades of research several fundamental questions remain unanswered. The HIV proteins to target in order to provide optimal protection against HIV remain unclear. CD8 + T cell responses clearly facilitate immune control of HIV/SIV (Jin et al., 1999; Koup et al., 1994; Kuroda et al., 1999) but did not protect humans from HIV-1 infection in a recent Adenovirus vector vaccine trial McElrath et al., 2008) . It has been widely viewed that an effective HIV vaccine would need to generate broad anti-HIV CD8 + T cell responses likely targeting as many proteins as possible (Betts et al., 1999; Chouquet et al., 2002) . However, recent studies suggest that there are significant differences in the efficacy of T cell immune responses to individual HIV antigens with the occurrence of both useful and potentially detrimental virus-specific T cell responses (Kiepiela et al., 2007; Ngumbela et al., 2008) . Gag-specific T cell responses have been shown to be particularly efficacious in controlling HIV viremia while Env-specific T cell responses appear to be less helpful (Kiepiela et al., 2007; Masemola et al., 2004; Zhuang et al., 2008) . Similarly, differences in suppressive efficacy of individual SIV epitope-specific T cell lines have also been documented (Loffredo et al., 2007; Loffredo et al., 2005) . As yet, however, there is no clear consensus regarding the optimal specificity and range of proteins that need to be targeted in order to establish long-term protection against HIV. While there is general agreement on the usefulness of targeting Gag antigens (Edwards et al., 2002; Masemola et al., 2004; Novitsky et al., 2003) , the utility of CD8 + T cells specific for other viral antigens remains unclear. Non-structural proteins of SIV and HIV-1 are also frequent targets of CTL responses Mothe et al., 2002) . In the wellcharacterized Indian rhesus macaque model of SIV infection, the Mamu-A⁎01 allele restricts both an immunodominant Tat and Gag CTL epitopes. However, the SL8 Tat epitope undergoes immune escape early and appears to contribute little to immune control of SIV, whereas the CM9 Gag tends to escape much later and is clearly associated with enhanced immune control of SIV Allen et al., 2000; O'Connor et al., 2002b) . Tat is a variable protein and whether all Tat epitopes are unhelpful or only a subset is not clear.
In order to study the utility of CD8 + T cell responses against individual viral proteins, we examined CD8 + T cell responses to SIV in a cohort of 32 pigtail macaques from a recent peptide-pulsed blood cell immunotherapy study (De Rose et al., 2008b) . In that study we found that inducing CD8 + T cell responses to SIV Gag alone was as effective at controlling viremia as inducing T cell responses to all SIV antigens. Furthermore, SIV Gag-specific CD8 + T cell responses were superior to Env-specific CD8 + T cell responses at delaying SIV disease progression (Peut and Kent, 2009 ). However, we now show that a large proportion of animals recognized a pool of SIV regulatory and accessory peptides. The majority of these responses were directed against SIV Nef and Tat. SIV Tat-specific CD8 + T cell responses were mapped to 2 novel epitopes restricted by the MHC class I Mane-A⁎10 allele. Sequencing across these Tat epitopes in the SIV infected animals Virology 388 (2009) 315-323 revealed several mutations conferring escape from CTL in both Tat epitopes. There was a clear difference in the rate of CTL escape between the 2 Tat epitopes suggesting constraints in immune escape at one of the Tat epitopes. Our results suggest vaccinating against particular epitopes within some HIV regulatory/accessory proteins may help contribute to subsequent viral control.
Results
Robust CD8 + T cell responses to SIV accessory and regulatory proteins following acute infection CD8 T cell responses to HIV-1 accessory and regulatory proteins are common in HIV-infected humans (Addo et al., 2002; Altfeld et al., 2001 ) but the frequency of responses to similar accessory and regulatory proteins in outbred pigtail macaques infected with SIV is not known. When assessed across a large study of SIV-infected pigtail macaques we found a combined pool of peptides spanning the 6 regulatory/accessory proteins were more commonly targeted than Gag, Env or Pol proteins (Fig 1a) . Eighteen out of thirty-two SIV mac251 -infected animals generated CD8 + T cell responses to a combined SIV accessory and regulatory protein (RTNVVV) peptide pool 4 weeks post infection (p.i.) (De Rose et al., 2008a) . By comparison, SIV Gag-, Poland Env-specific CD8 + T cell responses at the same timepoint were observed in only 4, 1 and 7 animals, respectively. By 14 weeks p.i., 16, 4, 9 and 28 out of 32 animals had SIV Gag-, Pol-, Env-and RTNVVVspecific CD8 + T cell responses, respectively. The SIV RTNVVV-specific
IFNγ CD8 + T cell responses ranged from 1-12% of total CD3 + CD8 + T cells. Responses to SIV proteins present in the vaccines (either Gag or all SIV proteins) were overall higher in animals receiving those vaccinations ( Fig. 1a shows a breakdown of responses by vaccine group), but the responses to the regulatory/accessory proteins were common across all groups. To determine which of the 6 regulatory/accessory proteins were most commonly targeted by CD8 T cell responses, we mapped responses to peptide pools spanning individual proteins in the 13 animals with responses to the combined pool exceeding 0.5% of CD8 T cells (Fig. 1b) . The frequency of responses to SIV regulatory/accessory proteins was Tat N Nef N Vif/Vpr N Vpx/Rev. Intriguingly, we noted that most animals targeting SIV Tat shared the MHC class I allele Mane-A⁎10 suggesting the possibility that Mane-A⁎10-restricted a SIV Tat CD8 + T cell epitope.
Identification of SIV Tat CD8 + T cell epitopes
To facilitate further study of common SIV regulatory/accessory protein specific CD8 + T cells we mapped SIV Nef-and Tat 
Mane-A⁎10
To determine the MHC restriction of SIV Tat KSA10-and KVA10-specific CD8 + T cells, we compared MHC class I genotyping of pigtail macaques responding to each epitope. Of the alleles typed for, only a single shared MHC class I allele, Mane-A⁎10, was common to SIV Tat KSA10 and KVA10 responders suggesting that both responses were likely restricted by Mane-A⁎10 (Table 1) . Further, we have previously identified an immunodominant Mane-A⁎10-restricted SIV Gag CD8 + T cell epitope KP9 (Gag 164-172 , KKFGAEVVP) (Fernandez et al., 2005; Smith et al., 2005b; Smith et al., 2005c) . The shared N-terminus lysine repeat sequence motif in SIV Gag KP9 and both SIV Tat KSA10 and KVA10 epitopes further suggested that the two Tat CD8 + T cell epitopes were also Mane-A⁎10-restricted. Since in vitro folding of MHC I/peptide complexes is intolerant of extensions or truncations to the optimal minimal peptide, we folded Tat KSA10 and KVA10 peptides with Mane-A⁎10 molecules in vitro. We successfully folded both Mane-A⁎10/Tat KSA10 and Mane-A⁎10/Tat KVA10 tetramers (not shown). We then used PE-labeled tetramers to stain PBMC obtained at week 3 and 14 after SIV infection of 12 of the 13 Mane-A⁎10 + animals from within the SIV infection study, including the animals with strong responses to these peptides identified by the earlier IFNγ ICS study (Table 2) . Tetramer staining with Mane-A⁎10 folded around either SIV Tat KSA10 or SIV Tat KVA10 peptides responses specific for the SIV Gag KP9 epitope by week 14. In contrast, at 3 weeks after SIV infection, responses to KVA10 and KP9 were much more common than responses to KSA10, suggesting that this epitope is subdominant early in infection. We also studied the avidity of the KSA10 and KVA10 tetramer binding, in comparison to the KP9 tetramer, to CD8 T cells obtained at week 14 from animal 8240 which had robust responses to all 3 epitopes. The avidity of CD8 T cells to all 3 epitopes was similar (Fig. 3 ).
CD8
+ T cells specific for SIV Tat KVA10 but not KSA10 select for escape mutations during acute SIV infection
Rhesus macaques that express the Mamu-A⁎01 MHC class I allele also respond to both a Gag (CM9) and a Tat (SL8) CTL epitope (Allen et al., 2000) . The Tat SL8 epitope, but generally not the Gag CM9 epitope, undergoes immune escape during acute SIV infection (Price et al., 2004) . Having identified 2 novel SIV Tat Mane-A⁎10-restricted epitopes, we sought to determine whether SIV Tat KSA10-and KVA10-specific CTL selected for escape mutations at these epitopes and compared them to the SIV Gag KP9 epitope. To assess putative CTL escape mutations within SIV Tat KSA10 and KVA10 we amplified Tat from plasma viral RNA and sequenced across both epitopes for all Mane-A⁎10 + animals at multiple timepoints from 2 through to 36 weeks p.i. (Table 3 ). Multiple non-synonymous mutations within Tat KVA10 were detected in most Mane-A⁎10 + animals as early as 3 weeks p.i. whereas mutations in Tat KSA10 were not detectable until at least 12 weeks p.i.. For comparison we also sequenced the same animals across the immunodominant SIV Gag KP9 epitope for which we have previously described selection of a specific CTL escape mutation (K165R) that exacts a significant fitness cost to the virus (Fernandez et al., 2005) . Similar to SIV Tat KSA10, no mutations were present within SIV Gag KP9 3 weeks p.i., but escape, predominantly to the K165R variant, was present in most animals by week 20 (Fig. 4) . Several mutations evolved within both SIV Tat KSA10 and KVA10 that were common to multiple animals although unlike the Gag KP9 epitope there was no single dominant pattern of mutation in either Tat epitope. Nonetheless, it appeared that mutations were somewhat more uniform within SIV Tat KSA10 than in Tat KVA10. Three mutations appeared in multiple animals within Tat KSA10 (A89T, A91T and S95P) whereas 5 mutations were detected in Tat KVA10 (K114E, K115E, V118M, E116K and V122M) in multiple animals. We next examined whether common mutations identified within the SIV Tat KSA10 and KVA10 epitopes were in fact CTL escape mutations. We selected putative CTL escape mutations in both epitopes which were shared by multiple animals and compared T cell recognition of variant peptides incorporating these mutations with wild-type peptides by IFNγ ICS on fresh blood. For SIV Tat KVA10 variant peptides tested there was a significant difference in T cell recognition even at the highest peptide concentration tested between wild-type KVA10 and variant peptides incorporating common mutations observed in sequencing across the epitope (Fig. 2c) . CD8 + T cell response to wild-type KVA10 peptide was sustained even at low peptide concentrations (down to 8 ng/ml) while recognition of variant peptides was completely abrogated indicating that the single K114E, K115E, V118M and dual K114E and A121E substitutions all confer escape from SIV Tat KVA10-specific CD8 + T cells. Analysis of T cell responses to wild-type SIV Tat KSA10 and variant peptides incorporating single A89T and A91T substitutions showed that A91T completely abrogated T cell recognition even at the highest peptide concentration tested while the A89T substitution had minimal effect on T cell recognition for all peptide concentrations tested (Fig. 2d ). This suggests that for SIV Tat KSA10, A91T but not A89T confers escape from SIV Tat KSA-specific CD8 + T cells. We did not detect any sequence variation within SIV Tat KSA10 and KVA10 epitopes in several animals not expressing the Mane-A⁎10 allele when plasma RNA was sequenced 16 to 20 weeks p.i. (data not shown), suggesting that the mutations observed in Mane-A⁎10 + animals evolved due to immune selection pressure by SIV Tat-specific CD8 + T cells.
Complete escape from SIV Tat KVA10-specific CD8 + T cells during acute infection
It has been suggested that the rate of CTL escape may be linked to functional avidity of the CTL response wherein CTL responses which rapidly select for escape mutations (i.e. acute-phase CTL escape) are of higher functional avidity than those which select for escape mutations later in infection (O'Connor et al., 2002b) . We therefore assessed the kinetics and extent of CTL escape within SIV Tat KSA10 and KVA10 in Mane-A⁎10 + macaque 9021 by cloning SIV Tat from plasma viral RNA and sequencing individual clones (Table 4 ). There was a clear difference between both the rate and extent of CTL escape within SIV Tat KSA10 and KVA10 epitopes. There was no evidence of CTL escape in SIV Tat KSA10 until 18 weeks p.i. and even after the emergence of CTL escape mutations at 18 weeks p.i. wild-type SIV Tat KSA10 sequence still accounted for at least 25% of the viral quasispecies out to 36 weeks p.i., the last timepoint tested. By contrast, CTL escape mutations in SIV Tat KVA10 were detected as Fig. 3 . Avidity of CD8 T cells for KSA10, KVA10, and KP9 epitopes. PBMC from animal 8240 obtained 14 weeks after SIV infection was stained with various dilutions of the Mane-A⁎10 tetramers. Previous titration series showed that the optimal dilution of tetramer staining for each tetramer was ∼1:500 (not shown). early as 3 weeks p.i. and from 14 weeks p.i. onwards 100% of KVA10 clones sequenced contained CTL escape mutations indicating complete escape from KVA10-specific CTL.
Discussion
HIV/SIV-specific CD8 + T cells clearly play a crucial role in controlling viral replication and an effective HIV vaccine will likely require generation of CD8 + T cell responses with potent anti-viral activity (Borrow et al., 1994; Goulder and Watkins, 2008; Jin et al., 1999; Koup et al., 1994) . Although numerous HIV epitopes have been identified there are clear differences in the efficacy of CD8 + T cells specific for different HIV/SIV protein antigens (Loffredo et al., 2005) . Escape from HIV/SIV-specific CD8 + T cells frequently undermines effective control of viral replication (Allen et al., 2000; Barouch et al., 2002; Borrow et al., 1997; Goulder et al., 1997; O'Connor et al., 2002a; Phillips et al., 1991) . Our group and others have shown that Gagspecific CD8 + T cells are more effective at controlling viral replication 
Results of bulk PCR sequence analysis including mixed bases. a Not determined.
than Env-specific CD8 + T cells (Kiepiela et al., 2007; Peut and Kent, 2009 (Table 5 ) (Allen et al., 2000; Barouch et al., 2003; Friedrich et al., 2004a; Loffredo et al., 2007) . Although both Tat SL8-and Gag CM9-specific CTLs are present at similar frequencies during acute SIV infection of rhesus macaques, only Tat SL8-specific CTL rapidly select for escape mutations during acute infection (Loffredo et al., 2007; Mothe et al., 2002) . We speculate that the SIV Tat KVA10 response in pigtail macaques is analogous to SIV Tat SL8 response, whereas the SIV Tat KSA10 response is more analogous to the SIV Gag KP9 and CM9 responses. In Mamu-A⁎01 + rhesus macaques, the difference in timing of escape of CTL epitopes has been linked to the "functional avidity" of the CTL response wherein CTL responses that drive rapid escape during acute infection are more potent and effective than those which select for escape mutations more slowly (O'Connor et al., 2002a) . We found similar avidity for all 3 Mane-A⁎10 restricted epitopes studied. Acute-phase CD8 + T cell responses rapidly kill virus-infected cells and facilitate control of virus but emergence of CTL escape mutations in these epitopes enables virus to persist. Indeed, in rhesus macaques, Tat SL8-specific CTLs have been shown to have potent antiviral activity during acute infection and in vitro studies confirm that Tat SL8-specific CTLs are more effective at suppressing viral replication than Gag CM9-specific CTL (Loffredo et al., 2005; Mandl et al., 2007) . However, there is little or no fitness cost associated with escape mutations in Tat SL8 and these mutations persist even in Mamu-A⁎01-animals (Friedrich et al., 2004a; Mandl et al., 2007) . By contrast, mutations in SIV Gag CM9 develop more slowly and are often accompanied by compensatory mutations in the flanking sequence and completely revert to wild-type in Mamu-A⁎01-animals (Friedrich et al., 2004a; Friedrich et al., 2004b; Peyerl et al., 2003) . Thus, it appears that while SIV Tat SL8-specific CTLs are potent inhibitors of viral replication during acute infection, Gag CM9-specific CTLs facilitate control of viral replication during chronic infection by targeting a constrained epitope less able to tolerate escape mutations. The comparative functional profiles of these SIV CD8 T cells (either ability to express multiple cytokines/chemokines or kill virus infected targets) could also impact upon their ability to select escape mutations but remains to be determined. The rapid and complete selection of mutations in SIV Tat KVA10, which persists through chronic infection, suggests that KVA10 mutations may be well tolerated by the virus and that SIV Tat KVA10-specific CD8 + T cells are only effective in controlling wild-type virus during acute-phase viremia. The KVA10-specific CTLs commonly declined later after acute infection, consistent with the early emergence of escape. By contrast, the slower generation of KSA10-specific CTLs and the slow emergence of mutations in SIV Tat KSA10 suggest that this epitope may be subdominant during early infection but potentially exact a greater fitness cost to viral replication. The persistence of the A89T mutation at later timepoints despite lack of significant escape from Tat KSA10-specific CD8 + T cells is also notable.
Additional studies testing virus with mutated SIV Tat KSA10 or KVA10 sequence in in vitro replication fitness assays or in vivo reversion studies in Mane-A⁎10 negative animals should further assess the utility of SIV Tat KSA10-and KVA10-specific CD8 + T cells. A prediction from our studies is that the region in Tat targeted by the KSA10 response is more functionally constrained (either within Tat or in the overlapping reading frames) compared to the KVA10 or SL8 regions of Tat. This can now be directly analyzed in functional studies by + animals with wild-type sequence across the SIV Tat epitopes KSA10 and KVA10 and the SIV Gag epitope KP9 is shown over time after SIV infection. The data is derived from Table 3 ; at least 9 of the 13 animals yielded viable sequence at each time point. Week N 10 refers to multiple time points sequenced between weeks 12-36 p.i.. Table 4 Cloning and sequencing across SIV Tat KSA10 and KVA10 epitopes in Mane-A⁎10 
Materials and methods

Animals
Thirty two pigtail macaques (Macaca nemestrina) with SIV mac251 infection examined in this study were part of a peptide-pulsed blood cell vaccine study (De Rose et al., 2008a) . Briefly, the animals were infected with SIV mac251 , placed on antiretroviral therapy from weeks 3-10 and vaccinated with autologous PBMC pulsed with overlapping 15-mer SIV Gag peptides (10 animals), overlapping 15-mer peptides spanning all SIV proteins (11 animals) at weeks 4, 6, 8 and 10 or unvaccinated controls (11 animals). The peptides were supplied by the NIH AIDS reagent repository. All animals were followed for viral load and disease progression. The SIV mac251 was kindly supplied by Drs N. Miller and R. Pal (Pal et al., 2002) and injected intravenously at 40 TCID50 as previously described (Batten et al., 2006) . Plasma SIV RNA levels were determined by real-time PCR as previously described (Dale et al., 2004) . All animals in this study had MHC typing for common MHC I alleles by RSCA as previously described (Pratt et al., 2006; Smith et al., 2005b) . The MHC typing included evaluating animals for the presence of the Mane-A⁎10 allele which restricts the immunodominant Gag CD8 + T cell epitope KP9.
Immunological assays
SIV-specific CD8 + T cell responses were evaluated using intracellular cytokine staining (ICS) for SIV-specific expression of IFNγ following in vitro peptide re-stimulation as previously described (De Rose et al., 2008a) . SIV mac239 and SIV mac251 complete peptide sets (#6204, 6205, 6207, 6443, 6448, 6449, 6450, 6883 and 8680) were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Briefly, 230 μl whole blood was incubated with 1 μg/ml/peptide overlapping 15-mer SIV mac239 peptides or dimethyl sufloxide (DMSO) control in the presence of co-stimulatory antibodies anti-CD28 and anti-CD49d (both from BD Biosciences/Pharmingen, San Diego CA, USA) and 10 μg/ml Brefeldin A (Sigma, St. Louis MO, USA) for 6 h. Cells were labeled with anti-CD3 PE (clone SP34-2) and anti-CD8 PerCP (clone SK1), red blood cells lysed with BD FACS Lysing Solution and remaining leukocytes permeabilized with BD Perm-2 then incubated with anti-human IFNγ APC (clone B27) (all from BD Biosciences) and fixed with 1% formaldehyde (Polysciences, Inc Warrington PA, USA) for FACS analysis.
Tetramer staining
Cryopreserved PBMC were used to stain CD8 + T cells with tetrameric complexes of the MHC class I protein Mane-A⁎10 folded around either SIV Gag KP9, SIV Tat KSA10 or SIV Tat KVA10 peptides, constructed as previously described (Smith et al., 2005c) and kindly provided by Dr Andrew Brooks. Briefly, PE-conjugated tetramer was added to 1 × 10 6 PBMC and incubated for 30 min at room temperature before addition of anti-CD3 Pacific blue (clone SP34-2) and anti-CD8 PerCP (clone SK1) (both from BS Biosciences) and a further incubation for 30 min at room temperature. Excess antibody was removed by washing cells first with FACS wash buffer followed by PBS before fixing cells with 1% formaldehyde.
Amplification of vRNA from plasma
Viral RNA was extracted from cell-plasma using the QIAmp viral RNA Mini kit (Qiagen) and cDNA prepared from each RNA sample using SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer's protocol. Hot Start High-Fidelity DNA Polymerase (Phusion) was used to amplify Gag and Tat viral sequences from cDNA by PCR according to manufacturer's protocol. The sense and antisense oligonucleotides used for PCR amplification were 5′-GAAAGGGGAAGGAGCAG-3′ and 5′-GAAAGGGGAAGGAGCAG-3′ for t h e M a n e -A ⁎ 1 0 -r e s t r i c t e d Ta t K S A 10 e p i t o p e , 5 ′ -GGCAATTGGTTTGACCTTGCT-3′ and 5′-CTTGTGGAAAGTCCCTGCTG-3′ for the Mane-A⁎10-restricted Tat KVA10 epitope and 5′-CACGCAGAA-GAGAAAGTGAA-3′ and 5′-GTTCCTGCAATRTCKGAT-3′ for Mane-A⁎10-restricted Gag KP9 epitope. The following cycling conditions were used for each amplification: 98°C for 30 s followed by 40 cycles of 98°C for 10 s, 58°C for 15 s, and 72°C for 1 min, with a final extension of 72°C for 10 min. The final PCR products were analyzed by 1% agarose gel electrophoresis and corresponding bands excised and purified using Qiagen gel purification.
Viral sequencing
SIV Gag and Tat PCR fragments were gel purified (Qiagen) and used for sequencing of bulk PCR products on an ABI3130xl genetic analyzer automated sequencer as previously described (Loh et al., 2007) . For analysis of individual cloned viral sequences, gel purified amplicons were cloned into pGEM-T Easy Vector (Promega) and direct sequencing of individual bacterial colonies was performed. Briefly, a single bacterial colony (∼ 2 mm) was transferred to 15 μl distilled water and resuspended by pipeting. The cell suspension was then heated at 92°C for 15 min and used as template for direct sequencing (Peut and Kent, 2007) . Chromatograms were carefully inspected using ContigExpress (Invitrogen).
Data analysis
Flow cytometric data was analyzed with FloJo software version 7.2.2 (Tree Star Inc, Ashland OR, USA). Background DMSO or tetramer FMO subtraction was performed for all SIV-specific responses reported.
